Hypoglycemia News and Research

RSS

Hypoglycemia, also called low blood glucose or low blood sugar, occurs when blood glucose drops below normal levels. Glucose, an important source of energy for the body, comes from food. Carbohydrates are the main dietary source of glucose.

Gastrointestinal progenitor cells could be coaxed into making insulin

A study by Columbia researchers suggests that cells in the patient's intestine could be coaxed into making insulin, circumventing the need for a stem cell transplant. Until now, stem cell transplants have been seen by many researchers as the ideal way to replace cells lost in type I diabetes and to free patients from insulin injections.

12 Mar 2012

XMetA can control blood glucose levels in patients with diabetes

XOMA Corporation announced that its study of XMetA, the company's fully-human allosteric monoclonal antibody to the insulin receptor, is available online and will be published in the May issue of the American Diabetes Association's journal Diabetes.

8 Mar 2012

Lilly, Boehringer Ingelheim announce availability of Jentadueto tablets

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced Jentadueto (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S.

8 Mar 2012

TAK-875 - an emerging therapy for Type 2 diabetes

In a trial of 426 patients with Type 2 diabetes, TAK-875 reduced blood sugar below a pre-determined level in as much as 48 percent of those receiving it after 12 weeks, compared with 40 percent of those who took glimepiride, the older drug, according to findings published online by The Lancet medical journal. The research was presented in June at the American Diabetes Association’s annual meeting in San Diego.

28 Feb 2012

TAK-875 as effective as glimepiride in treating type 2 diabetes

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

27 Feb 2012

New drug improves glycaemic control with minimum risk of hypoglycemia in type 2 diabetics

27 Feb 2012

The Lancet publishes Takeda's TAK-875 Phase 2 data on type 2 diabetes

Phase 2 clinical data of an investigational type 2 diabetes therapy, TAK-875 of Takeda Pharmaceutical Company Limited, were published online first in The Lancet.

27 Feb 2012

Evergreen receives Advanced Certification in Inpatient Diabetes from The Joint Commission

Evergreen Healthcare has earned Advanced Certification in Inpatient Diabetes from The Joint Commission for its comprehensive diabetes treatment program, establishing it as Washington state's only program to currently hold the distinction.

18 Feb 2012

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion in the European Union for the expanded use of BYETTA (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.

17 Feb 2012

Oxygen deprivation disrupts insulin and glucose regulation in rat pups

Premature infants' immature lungs and frequent dips in blood pressure make them especially vulnerable to a condition called hypoxia in which their tissues don't receive enough oxygen, sometimes leading to permanent brain damage. New animal research suggests that a common practice in caring for these babies might in fact exacerbate this condition, increasing the chances for long-term neurological deficits.

14 Feb 2012

Automated insulin pump delivery can reduce hypoglycemia in individuals with type 1 diabetes

An automated on/off feature built into insulin pump systems can suspend insulin delivery when it detects low blood glucose levels (via continuous glucose monitoring), significantly reducing the severity and duration of hypoglycemia in individuals with type 1 diabetes, according to a study published in Diabetes Technology & Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc.

10 Feb 2012

Merck receives FDA approval for JANUMET XR to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration approved JANUMET XR (sitagliptin and metformin hydrochloride extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA (sitagliptin), with extended-release metformin.

3 Feb 2012

Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.

31 Jan 2012

Echo commences Symphony tCGM System trials in critical care patients

Echo Therapeutics, Inc., a company developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude SkinPrep System for transdermal drug delivery, today announced that it is initiating clinical studies of its Symphony tCGM System in critical care patients.

25 Jan 2012

ADHD diet: Review of studies

A new review finds that some foods may not be good for children with attention deficit-hyperactivity disorder (ADHD). Fast foods, red meat, processed foods, soft drinks, high fat dairy foods and potato chips may not be right.

10 Jan 2012

Perrigo signs definitive agreement to acquire assets of CanAm Care

Perrigo Company today announced that it has signed a definitive agreement to acquire substantially all of the assets of CanAm Care, a privately-held, Alpharetta, Georgia-based distributor of diabetes care products for approximately $36 million in cash.

9 Jan 2012

Medtronic introduces mySentry Remote Glucose Monitor in the U.S.

Today, Medtronic, Inc. announced U.S. Food and Drug Administration (FDA) approval and U.S. market launch of the first-of-its-kind mySentry Remote Glucose Monitor, which allows a parent or caregiver to monitor from another room a patient's MiniMed Paradigm REAL-Time Revel System.

From Medtronic 4 Jan 2012

Obstacles people with type 2 diabetes face that prevent them from getting ultimate treatment

Eli Lilly and Company today announced it is conducting the first major international, prospective observational study designed to understand the real-world obstacles that people with type 2 diabetes face that prevent them from reaching their ultimate treatment goals.

2 Dec 2011

JDRF supports FDA's draft guidance on artificial pancreas technology

The JDRF today said it is encouraged that the Food and Drug Administration (FDA) has issued a draft guidance which appears to lay a foundation for accelerating the development and availability of artificial pancreas technology (AP) that will improve the lives of millions of Americans living with type 1 diabetes.

2 Dec 2011

FDA approves Medtronic's iPro2 Professional continuous glucose monitoring system

Medtronic, Inc. today announced the Food and Drug Administration (FDA) approval of iPro2, a next generation Professional continuous glucose monitoring (CGM) system and the latest in a series of recent diabetes technology approvals and innovations from the company.

From Medtronic 22 Nov 2011